The analysis of multiomics biomedical data has become increasingly critical in clinical decision-making for brain diseases, such as Alzheimer's disease (AD). However, the inherent fuzziness of ...

Q2 2025 Earnings Conference Call August 8, 2025 8:00 PM ETCompany ParticipantsElizabeth Krutoholow - Vice President of ...

Shares in health technology group Tempus AI ($TEM) raced 7% higher today after its Q2 revenues surged on cancer testing demand. Forecast Busting ...

In trading on the Nasdaq stock market as of 1:17 p.m. Central, Tempus' stock price was trading at $60.65, up 3.2% from the ...

These 10 stocks could mint the next wave of millionaires › Tempus AI (NASDAQ:TEM), a technology company that applies artificial intelligence to precision diagnostics and healthcare data, reported its ...

The firm's genomics revenues more than doubled year over year, while data and services revenue increased nearly 36 percent.

Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product ...

Tempus AI (NASDAQ:TEM) stock sees a 9% pre-market gain as the company raises its 2025 revenue outlook amid strong Q2 ...

Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...